Recent Advances in Manufacturing, Production, and Characterization of Antibody-Based Therapeutics
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".
Deadline for manuscript submissions: closed (28 February 2023) | Viewed by 11763
Special Issue Editor
Special Issue Information
Dear Colleagues,
Therapeutic monoclonal and bispecific antibodies have become some of the fastest growing emergent drugs, providing treatments for cancer, immunological, inflammatory disorders, and more recently, for COVID-19 disease. Recent research and technological innovations have significantly contributed towards the discovery, development, manufacturing, production, and characterization of these complex drug molecules. Novel antibody engineering technologies have enhanced therapeutic efficacy and minimized immunological side effects, which has led to faster commercialization of antibody-based therapeutics. The advent of bispecific antibodies has further revolutionized this research area in which numerous molecular formats, structural diversity, and related manufacturing and development processes have been continuously explored to target variety of antigens.
The aim of this Special Issue is to offer to our readers recent research and technological advances in the broad area of therapeutic antibodies, including drug design and discovery, development, manufacturing and production, mechanisms of action and characterization.
Dr. Nishant Mohan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug discovery
- monoclonal antibodies
- bispecific antibodies
- biomolecules
- manufacturing
- antibody engineering
- antibody production
- antibody characterization
- mechanism of action
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
